In previous studies we showed that a chronic colitis associated with a Thl T cell response can be induced by the rectal administration of the haptenizing reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS). We report here that oral administration of haptenized colonic proteins (HCP) before rectal administration of TNBS effectively suppresses the ability of the latter to induce colitis. This suppression (oral tolerance) appears to be due to the generation ofmucosal T cells producing TGF-[3 and Th2-type cytokines after oral HCP administration. Peyer's patch and lamina propria CD4+ T cells from HCP-fed animals stimulated with anti-CD3/anti-CD28 had a 5-10-fold increase in their production of TGF-[3 and secreted increased amounts oflL-4 and IL-10 but lower levels oflFN-~ in comparison to T cells from ovalbumin-fed control animals. In addition, the colons of HCP-fed mice showed strikingly increased TGF-[3 but decreased IL-12 expression by immunohistochemicat studies and isolated mononuclear cells from HCP-fed animals secreted less IL-12 heterodimer. Finally, and most importantly, the suppressive effect of orally administered HCP was abrogated by the concomitant systemic administration ofanti-TGF-[3 or rlL-12 suggesting a reciprocal relationship between IL-12 and TGF-[3 on tolerance induction in TNBS-induced colitis. In parallel studies we demonstrated that TNBS-induced colitis can be transferred to naive recipient animals with purified CD4+ T cells from the colon of TNBS-treated animals and that such animals develop lethal pancolitis when exposed to very low doses of TNBS. Feeding of HCP suppressed this sensitivity to TNBS, indicating that oral feeding can suppress the response of pre-committed T cells in vivo. These studies suggest for the first time that TGF-[3 production can abrogate experimental granulomatous colitis even after such colitis is established, and thus, that regulation of TGF-[3 levels may have relevance to the treatment of human inflammatory bowel disease.
O
ral administration of autoantigens and the consequent induction of oral tolerance have been shown to suppress experimental autoimmune diseases in animal models, such as in experimental autoimmune encephalomyelitis (1, 2) , collagen-(3) and adjuvant-induced arthritis (4) , diabetes in the non-obese (NOD) 1 mouse (5) and autoimmune uveitis (6, 7) . Recent studies have suggested that the dose of fed antigen is an important factor in determining the mechanism of such "oral tolerance". Whereas high doses of antigen have been suggested to favor clonal deletion or clonal anergy ofThl T cells, low doses of antigen may induce ac1Abbreviations used in this paper: CD, Crohn's disease; CMFDA, 5-chloromethylfluorescein diacetate; DC, dendritic cells; HPC, haptenized colonic protein; HPF, high power field; IBD, inflammatory bowel disease; LP, Lamina propria; NOD, non-obese; PP, Peyer's patch; TNBS, 2,4,6-trinitrobenzene sulfonic acid. tive suppression of Thl T cells resulting in the generation of T cells that secrete TGF-[3, IL-4, and IL-10 (2, 8, 9) . Regardless of the mechanism involved, it is possible that induction of oral tolerance can be used to treat autoimmune disease in humans, and clinical trials exploring this approach for the treatment of multiple sclerosis, rheumatoid arthritis, and uveoretinitis are under way.
Inflammatory bowel disease (IBD) encompasses Crohn's disease (CD) and ulcerative colitis, the major chronic inflammatory diseases of the gastrointestinal tract in humans (10, 11) . Recently, various animal models of chronic intestinal inflammation have been established which will likely provide new insights into the pathogenesis of IBD. These include rats carrying transgenes for HLA-B27 and [32-microglobulin (12) , T cell reconstituted Tg~26 mice transgenic for the human CD3~ gene (13) , and mice in which the genes for IL-2 (14) , IL-10 (15), Gcq2 (16) , and the alpha or beta chain of the T cell receptor (17) have been inactivated by homologous recombination. In addition, a T h lmediated granulomatous colitis model has been established by the adoptive transfer of normal CD45R.B hi T cells from B A L B / c mice to C.B.-17 scid mice (18) . Importantly, the C D 4 5 R B l~ C D 4 + T cell population did n o t cause disease and, if injected together with the CD45R_B hi population, prevented disease induction (18) ; in addition, this prevention could be reversed by adding antibodies to TGF-[3, suggesting a key negative role for this cytokine in disease induction. TGF-13 is a pluripotent cytokine that functions as potent inhibitor of T and B cell proliferation and cytokine production by macrophages (19) . T h e importance o f this inhibitory function is underscored by the finding that TGF-[31 null mice show multiorgan inflammation, excessive lymphocytic infiltrations, and early death (20, 21) . W e have previously described a T H 1 model of chronic intestinal inflammation in mice induced by rectal administration of the hapten reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS) (22) . In the present study, we demonstrate that T N B S -i n d u c e d colitis can be adoptively transferred to normal mice by in vivo primed lamina propria C D 4 + T cells and that T N B S -i n d u c e d colitis can be suppressed by T G F -[3-mediated oral tolerance in mice fed haptenized colonic proteins even after transfer o f p r e c o m m i t t e d T cells. These results suggest that oral tolerance and the regulation of TGF-[3 levels may have relevance to the treatment of h um a n inflammatory bowel disease. • (B) HE-stained cross colon section of a mouse that received CD4+ T cells from diseased animals and was challenged with low doses of TNBS at day 7 after the transfer. There was a loss of goblet cells, colon wall thickening, and severe transmural inflammation in the colon.
• 100. (C) IFN-~ secretion by LP CD4+ T cells in normal SJL/J mice, TNBS-treated mice and mice that received CD4+ T cells from mice with TNBS-induced colitis or control ethanol-treated animals 7 d after the cell transfer. Some mice that received the CD4+ T cells were challenged 6 d after the transfer with 0.02 mg TNBS and LP CD4+ cells were isolated the following day. Supernatants of cultured LP CD4 + T cells were removed after 2 d and analyzed for IFN-~/concentration by specific ELISA. A second independent experiment gave similar results, (D) HE-stained cross colon section of a mouse that received CD4+ T cells from control ethanol-treated animals and was challenged with low doses of TNBS at day 7 after the transfer. There was neither colon wall thickening nor severe transmural inflammation, X 100.
Material and Methods
Induction of Colitis. Specific pathogen-free 2-4-mo-old female SJL/J mice were obtained from the National Cancer Institute (NCI, Bethesda, MD) and maintained as described (22) . TNBScolitis was induced as previously described (22) .
Cell Isolation and Purification of Lamina Propria CD4+ T Cells.
Lamina propria (LP) lymphocytes were isolated from freshly obtained colonic specimens using the technique of Van der Heijden and Stok (23) modified as previously described (22) . The resultant cells were fu~her enriched by negative selection using mouse CD4 + T cell isolation columns (Isocell; Pierce Co., Rockford, IL) (22 Immunofluorescence. To obtain cryosections, tissue samples were taken at indicated time points and put into OCT-compound on dry ice; sections were cut in a dark room according to standard procedures. CMFDA + cells were visualized on a fluorescence microscope at an excitation wavelength of 490 nm.
Challenge of Mice That Received CD4+ T Cells with TNBS.
In some experiments, mice that received CD4+ T cells were challenged 6 d after transfer by rectal administration of 0.02 mg TNBS.
Grading of Histologic Changes. Tissues were removed at indicated time points and processed as described (22) . The degree of inflammation on microscopic cross sections of the colon was graded semiquantitatively from 0 to 5, as previously described (22) . 
Generation of Haptenized Colonic Proteins.

Cell Culture of T Cells. Cell cultures of T cells were performed
in complete medium consisting of RPMI-1640 supplemented with 3 mM r-glutamine, 10 mM Hepes buffer, 10 Ixg/ml gentamycin, 100 U/mi each of penicillin and streptomycin, 0.05 mM 2ME, and 10% heat-inactivated FCS. For TGF-[3, cell cultures of enriched T cells were performed in serum free medium (GIBCO BRL, Gaithersburg, MD) supplemented as above.
Reagents and Monoclonal Antibodies. Cytokine Assays. To measure cytokine production, 24-well plates (Costar, Cambridge, MA) were coated with 10 I*g/ml murine anti-CD3~ antibody in carbonate buffer (pH 9.6) overnight at 4~ 10 s LP CD4+ T cells were then cultured in 1 ml of complete medium in precoated or uncoated wells and 1 b~g/ml soluble anti-CD28 antibody was added to the anti-CD3~-coated wells.
Cultures were incubated at 37~ in a humidified incubator containing 6% CO2. After 48 h (after 60 h for TGF-[3), culture supernatants were removed and assayed for cytokine concentration (IFN-"/, IL-4, and IL-10) by specific ELISA (PharMingen). TGF-~ concentrations were determined using the Predicta TGF-13 ELISA Assay (Genzyme Corp.). Optical densities were measured on a ELISA reader (MR 5000; Dynatech Labs., ChantiUy, VA) at a wavelengh of 490 nm.
Heterodimer-specific Elispot Assay for Interleukin-12.
Macrophageenriched cells from the lamina propria were obtained from lamina propria mononudear cell population using an adherence technique as described for isolation of spleen dendritic cells. In these studies however, macrophage adherent cell population were isolated. Immunohistochemistry. Cryosections (7 p,m) were air dried, fixed in cold acetone for 3 man at RT, incubated in 0.6% H20 2 in methanol for 30 man, rehydrated in PBS plus 0.01% Triton-X for 15 man, blocked with 100% normal rabbit serum for 3 h, and then incubated with the primary antibody (rat anti-mouse IFN-"/ or chicken anti-mouse TGF-~; 1:100 dilution in 10% normal rabbit serum) overnight at 4~ in a dark humid chamber. 
Results
Adoptive Transfer of TNBS-induced Colitis by Lamina Propria CD4+ T Cells to Normal SJL/J Mice.
We have previously described the induction of a chronic granulomatous colitis in normal BALB/c and SJL/J mice by rectal administration of the haptenizing reagent 2,4,6 trinitrobenzene sulfonic acid, a colitis dominated by CD4+ T cells producing Thl-type cytokines (22) . To further explore this observation, we initially sought to determine whether the development of TNBS-induced lesions could be adoptively transferred to naive animals with CD4+ T cells. Accordingly, we isolated LP CD4+ T cells from TNBS-treated (diseased) animals or control ethanol-treated animals and injected them into normal SJL/J mice. Whereas recipients ofCD4+ T cells from control animals did not develop colitis upon transfer, recipients of CD4+ T cells from diseased animals developed mild colitis. Thus, the colons of the latter animals were found to contain lymphocytic infiltrates, located mainly in the subepithelial areas, that produced IFN-',/ (Fig. 1 a) . Moreover, these infiltrates contained injected CD4+ T cells, since CD4+ T cells that were labeled in vitro with CM-FDA before transfer (see Materials and Methods) were demonstrated by fluorescence microscopy in the colons at the 7-d post-transfer time point (data not shown).
To verify the presence of hapten-specific CD4+ T cells in the lesions of the recipient mice, we administered to some of the mice low doses of TNBS that were shown in control experiments not to cause inflammation in normal mice. We found that the challenged mice that had received T cells from mice with TNBS-colitis developed a massive pancolitis and died within 36 h (Fig. 1 b) . Furthermore, analysis of IFN-~/ secretion by LP CD4+ T lymphocytes from these mice showed very high production of IFN-',/ (Fig. 1 c) . In contrast, the colons of challenged mice that had received T cells from ethanol-treated animals appeared histologically normal (Fig. 1 d) and LP CD4+ T cells secreted low amounts of IFN-~/ that were comparable to those produced by CD4+ T cells from normal mice (Fig. 1  c) . Taken together, these studies provide strong support for the view that TNBS-induced colitis is mediated by IFN-~/-producing CD4+ T cells that are present in colonic tissues.
Active Suppression of TNBS-induced Colitis by Feeding of Haptenized Colonic Proteins.
We next turned our attention to the question of whether TNBS-induced colitis can be suppressed by inducing "oral tolerance" (i.e., unresponsiveness to fed antigen) specific for TNBS-HCP. We generated in vitro HCP using previously described techniques (see Materials and Methods) and obtained colonic proteins with (Fig. 2 a) , mice fed HCP failed to develop diarrhea and weight loss, and their colons appeared macroscopically intact (Fig. 2 b) . Furthermore, these mice showed no histologic signs of severe colitis (Fig. 2 c) . In contrast, mice fed OVA showed clear macroscopic (Fig.  2 b) and histologic ( Fig. 2 d) evidence of colitis that was indistinguishable from that in normal mice given TNBS. Furthermore, TNP-KLH-fed mice showed less weight loss than OVA-fed mice but still exhibited colonic inflammation, as assessed by histologic analysis ( Table 1 ), suggesting that the tolerance observed after feeding of HCP might be at least partially due to the TNP itself.
Since these results showed that TNBS-induced colitis can be prevented by feeding of HCP, we next analyzed whether HCP would also be protective when disease was transferred by LP CD4+ T cells from mice with TNBS-induced colitis. In these experiments, we isolated colonic LP CD4+ T cells from mice with TNBS-induced colitis at day 10, and transfered these cells to normal mice. The recipient mice were fed four times with HCP and then, after an additional 4 d 0.5 mg TNBS was administered per rectum. As shown in Fig. 2 e, oral feeding of HCP suppressed colitis induced by the transfer of in vivo primed CD4+ T cells. These results suggest that the inflammation secondary to stimulation of preexisting TNBS-specific CD4+ T cells is inhibited by the induction oral tolerance.
LP CD4+ T Cells and PP T Cells in HCP-fed Tolerized Mice Display Reduced Proliferative Capacity and Secrete High Amounts ofTGF-fl, IL-4, andlL-lO.
To determine the mechanisms underlying the tolerance induced by feeding of HCP, we next focused on the capacity of intestinal LP cells in HCPand OVA-fed mice to produce various cytokines. Since previous studies had shown that TNBS-induced colitis is critically dependent on IL-12 levels (22), we first analyzed the ability ofmacrophage-enriched LP cells from HCP-fed tolerized mice to secrete functionally active IL-12 heterodimer. We found that cells from the LP of HCP-fed mice secreted strikingly less IL-12 heterodimer than those from the lamina propria of OVA-fed mice (4.2 + 0.8 vs. 69 + 12 spot forming cells per HPF). Furthermore, as assessed by immunohistochemistry, there was a marked reduction in IL-12 heterodimer expression by macrophages in the colon of HCP-fed mice compared with those from OVA-fed mice (data not shown) suggesting that IL-12-dependent Thl cell development was suppressed in .HCP-fed mice.
This hypothesis was supported by the analysis of IFN-y production in tolerized mice 7 d after TNBS administration. In these studies, we stimulated LP CD4+ T cells with anti-CD3/anti-CD28 and measured the concentration of IFN-y in culture supematants. As shown in Fig. 3 a, LP CD4+ T cells from TNBS-treated mice that were fed OVA produced large amounts of IFN-'y at day 7 (compared with mice not treated with TNBS), while T cells from mice fed HCP produced strikingly lower amounts of IFN-% In contrast, as shown in Table 2 , secretion of IL-4 and IL-10 was significantly higher in HCP-fed mice than in OVA-fed mice (P ~<0.01).
In additional studies, we measured TGF-]3 production by LP CD4+ and PP T cells in OVA-and HCP-fed mice. In this case, we stimulated both LP CD4+ T cells and PP T cells either with anti-CD3/anti-CD28 or with isolated dendritic cells loaded with HCP. As shown in Fig. 3, b and c, TGF-[3 production by both cell populations and both methods of stimulation was strongly increased in cells from mice fed HCP compared with cells from mice fed OVA. Additional studies showed that FACS| anti-CD3/anti-CD28-stimulated CD4+ T cells from the lamina propria of HCP-fed mice produced higher levels of TGF-f3 than those from OVA-fed mice (1.2 ng/ml vs. 0.1 ng/ml). To obtain direct evidence of TGF-[3 production in vivo, we performed immunohistochemical staining for this cytokine. As shown in Fig. 3, d-f , there was an increase in staining intensity for TGF-[3 by LP cells in HCP-fed animals compared with OVA-fed control animals after TNBS challenge. Finally, we measured the proliferation of PP T cells from HCP and OVA-fed mice. We found that PP T cells from mice fed HCP when stimulated with anti-CD3 and anti-CD28, proliferated significantly less than cells from mice fed OVA (P ~<0.01) suggesting that the proliferation of these cells was actively suppressed by increased TGF-~ secretion (Table 3) . 1.00 mg ratlgG gate tolerance and allow development of TNBS-induced lesions. To explore this possibility, we treated mice in vivo with anti-TGF-[3 or contol IgG on days 0, 4, 7, and 11 after feeding HCP. As shown in Fig. 4 a, anti-TGF-[3 treatment abrogated the protective effects of feeding of H C P on TNBS-induced colitis in a dose-dependent manner. The anti-TGF-[3-treated mice displayed clinical and histologic signs of colitis (Fig. 4 b) similar to those observed in T N B Streated mice. In addition, cytokine profiles o f L P C D 4 + T cells in HCP-fed, anti-TGF-[3-treated mice were similar to those of mice given TNBS intrarectally in the absence of feeding H C P (Table 4) . These studies, together with the TGF-[3 production studies described above, strongly suggest that TGF-[3 mediates the protective effect of feeding of H C P in TNBS-induced colitis.
Suppression of TNBS-induced Colitis by Feeding of Haptenized Colonic Proteins Can Be Abrogated by High Doses of rlL-12.
In further studies, we tested whether increased levels of IL-12 could counteract the suppressive effect of oral antigen administration. To test this hypothesis, we systemically administered IL-12 to mice that were fed H C P and then examined the effects of such treatment on the clinical course of the TNBS-induced disease. As depicted in Fig. 5 , when high doses of IL-12 were administered, a striking reduction of the suppression of TNBS-induced colitis by feeding of H C P was seen. In contrast, systemic administration of antibodies to IL-12 augmented the suppressive effects seen after feeding of H C P in T N B Sinduced colitis (data not shown). These results establish the reciprocal functional relationship between IL-12 and TGF-[3 on tolerance induction in TNBS-induced colitis. 
Systemic Administration of TGF-fl Prevents TNBS-induced
Discussion
In the present study we explore the cellular mechanisms that regulate experimental TNBS-induced cohtis. First, we show in adoptive transfer studies that TNBS-induced colitis can be mediated by C D 4 + T cells that home to colonic tissue. Second, we demonstrate that TNBS-induced colitis can be actively suppressed via oral tolerance by feeding of H C P and that such tolerance is critically dependent on TGF-[3 production by intestinal cells. Third and finally, we show that colitis due to transferred C D 4 + T cells can be suppressed by feeding of HCP, indicating that the oral tolerance mechanism affects precommitted T cells and thus HCP-fed or unfed mice were treated with ethanol or TNBS and some mice received injections with antibodies to TGF-[3 at days 0, 4, 7, and 11. LP CD4+ cells were isolated 9 d after administration of TNBS or ethanol. Culture supernatants were removed after 2 d and analyzed for cytokine concentration by specific ELISA. A slight increase in IFN-'y production was found in ethanol-treated mice that were given anti-TGF-[3 compared with ethanol-treated mice. A second independent experiment gave similar results.
may be relevant to the treatment of inflammatory bowel disease in humans. Inflammatory bowel diseases comprising Crohn's disease (CD) and ulcerative colitis are thought to be immunologically mediated diseases of the gastrointestinal tract (11) . Re- CD in humans and CD4+ T cells in both diseases reveal a Thl cytokine pattern that is consistent with the cytokine pattern found in CD (Fuss, I., M. Neurath, M. Boirivant, J. Klein, C. de la Motta, S. Strong, C. Fioccihi, and W. Strober, manuscript in preparation). In the CD45RB hi transfer model, it was shown that treatment of mice with antibodies to IFN-y ameliorates disease, whereas in the TNBS model, it was shown that anti-IL-12 (which downregulates IFN-'y production) abrogates disease even after the disease is well established. Further insight into the regulation of experimental colitis was gained in the present studies of TNBS-induced colitis in which the effect of induction of oral tolerance to TNBShaptenated colonic proteins on TNBS-induced colitis was determined. In particular, we showed that prefeeding of HCP to mice not only prevented TNBS-induced colitis at the clinical and histologic level but also prevented the Thltype T cell response that accompanies and presumably mediates this colitis. In addition, regarding the mechamsm of the oral tolerance, we showed that tolerization to HCP was accompanied by elevated production of Th2-type cytokines and strikingly increased TGF-[3 secretion in mucosal tissues (in PP and LP) in vivo. Finally, we found that oral tolerance was abrogated in mice administered anti-TGF-[3 and that systemic adminstration of TGF-[3 prevented TNBS-induced disease. These results indicate clearly that TGF-[3 is a necessary condition for the establishment of oral tolerance to TNBS-haptenated colonic proteins.
In further studies, we showed that T cell-enriched LP and PP cells from tolerized animals produce high amounts of TGF-~ upon in vitro stimulation and displayed reduced proliferative capacities. The observation that fed HCP prevented TNBS-induced colitis via induction of cells producing TGF-[3 supports and extends the work of Miller et al. (25) who demonstrated the presence of bystander suppression mediated by TGF-[3 after feeding of antigen. Weiner (9, (25) (26) (27) has recently proposed that mucosally derived TGF-[3-producing CD4+ T cells are a special T helper subset that is induced upon low-dose oral antigen administration, provides mucosal T helper function and downregulates Thl T cell function. After their induction, such cells may migrate to other tissues including the lamina propria, where they exert TGF-[3-mediated suppressive effects on CD4+ T cells and macrophages that might otherwise cause inflammation. This suppressor mechanism could explain the protective effect of feeding of TNBS-haptenated proteins on TNBS-induced colitis. In particular, since TGF-[3 has been shown to be a potent inhibitor of IL-12-induced Thl development (28) , TGF-[3-producing cells generated upon feeding may prevent IL-12-dependent Thl cell development upon which TNBS-induced colitis is critically dependent (22) . Furthermore, oral tolerance induction led to a striking reduction of IL-12 heterodimer secretion by LP cells that might further account for the suppression of Thl cytokine production. Finally, taken together with the fact that administration of exogenous IL-12 abrogates tolerance induction, the results suggest a reciprocal functional relationship between IL-12 and TGF-13 on tolerance induction in TNBS-induced colitis.
The concept of induction of oral tolerance mediated by TGF-[3 has important implications to the treatment of autoimmune diseases generally: for instance, it has been shown that one can suppress PLP peptide-induced experimental autoimmune encephalitis by feeding MBP or antigeninduced arthritis by feeding collagen type II. These findings have led to the design of a rational immunotherapy for patients with rheumatoid arthritis (29) and multiple sclerosis (30) and promising clinical trials are currently in progress. The present data, in showing that TNBS-induced colitis can be actively suppressed by feeding HCP via induction of TGF-[3 secretion in the mucosal tissues and that oral tolerance can also abrogate experimental colitis when disease was transferred by LP CD4+ T cells, suggest that induction of oral tolerance has therapeutic relevance to immunologic diseases of the gastrointestinal tract, such as Crohn's disease.
